These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 17143509)
1. ERG upregulation and related ETS transcription factors in prostate cancer. Rostad K; Mannelqvist M; Halvorsen OJ; Oyan AM; Bø TH; Stordrange L; Olsen S; Haukaas SA; Lin B; Hood L; Jonassen I; Akslen LA; Kalland KH Int J Oncol; 2007 Jan; 30(1):19-32. PubMed ID: 17143509 [TBL] [Abstract][Full Text] [Related]
2. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440 [TBL] [Abstract][Full Text] [Related]
3. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979 [TBL] [Abstract][Full Text] [Related]
4. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma. Camões MJ; Paulo P; Ribeiro FR; Barros-Silva JD; Almeida M; Costa VL; Cerveira N; Skotheim RI; Lothe RA; Henrique R; Jerónimo C; Teixeira MR PLoS One; 2012; 7(11):e49819. PubMed ID: 23185447 [TBL] [Abstract][Full Text] [Related]
5. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175 [TBL] [Abstract][Full Text] [Related]
6. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932 [TBL] [Abstract][Full Text] [Related]
7. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue. Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209 [TBL] [Abstract][Full Text] [Related]
8. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. Smit FP; Salagierski M; Jannink S; Schalken JA BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236 [TBL] [Abstract][Full Text] [Related]
9. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677 [TBL] [Abstract][Full Text] [Related]
10. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. Hagen RM; Adamo P; Karamat S; Oxley J; Aning JJ; Gillatt D; Persad R; Ladomery MR; Rhodes A Am J Clin Pathol; 2014 Oct; 142(4):533-40. PubMed ID: 25239421 [TBL] [Abstract][Full Text] [Related]
12. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688 [TBL] [Abstract][Full Text] [Related]
13. Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines. Simpson S; Woodworth CD; DiPaolo JA Oncogene; 1997 May; 14(18):2149-57. PubMed ID: 9174050 [TBL] [Abstract][Full Text] [Related]
14. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504 [TBL] [Abstract][Full Text] [Related]
15. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Clark J; Attard G; Jhavar S; Flohr P; Reid A; De-Bono J; Eeles R; Scardino P; Cuzick J; Fisher G; Parker MD; Foster CS; Berney D; Kovacs G; Cooper CS Oncogene; 2008 Mar; 27(14):1993-2003. PubMed ID: 17922029 [TBL] [Abstract][Full Text] [Related]
16. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Petrovics G; Liu A; Shaheduzzaman S; Furusato B; Sun C; Chen Y; Nau M; Ravindranath L; Chen Y; Dobi A; Srikantan V; Sesterhenn IA; McLeod DG; Vahey M; Moul JW; Srivastava S Oncogene; 2005 May; 24(23):3847-52. PubMed ID: 15750627 [TBL] [Abstract][Full Text] [Related]
17. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199 [TBL] [Abstract][Full Text] [Related]
18. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key? Adler D; Lindstrot A; Ellinger J; Rogenhofer S; Buettner R; Perner S; Wernert N Mol Med Rep; 2012 Feb; 5(2):313-6. PubMed ID: 22038307 [TBL] [Abstract][Full Text] [Related]
19. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613 [TBL] [Abstract][Full Text] [Related]
20. Truncated ERG proteins affect the aggressiveness of prostate cancer. Wu F; Ding S; Lu J Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]